Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use

Abstract

Background:

Young to middle-aged women are more likely than men to be diagnosed with irritable bowel syndrome (IBS). Immune dysfunction may be present in IBS, however, few studies have tested whether hormonal contraceptive use is linked to inflammatory markers. The purpose of this study was to compare cytokine levels between women (ages 18–45) with and without IBS and with and without hormonal contraceptive use and to examine the relationships of cytokine levels to IBS gastrointestinal (GI) and non-GI symptoms within those using and not using hormonal contraceptives.

Methods:

Seventy-three women with IBS and 47 healthy control women completed questionnaires (demographics, hormonal contraceptive use) and kept a 28-day symptom diary. Fasting plasma and LPS-stimulated pro-inflammatory (IL-1β, IL-6, IL-12p40, IL-12p70, IL-8, and TNF-α) and anti-inflammatory (IL-10) cytokines were assayed.

Results:

No differences were found in plasma or stimulated cytokine levels between IBS and control women. Levels of IL-1β (p = 0.04) and TNF-α (p = 0.02) were higher among women who did not use hormonal contraceptives compared to women who used hormonal contraceptives. Among women with IBS, significant correlations were found between daily psychological distress and plasma IL-10, IL-12p70, IL-1β, IL-6, and IL-8 cytokine levels.

Conclusions:

These results suggest that hormonal contraceptive use might reduce IL-1β and TNF-α cytokine levels in women with IBS. The impact of hormonal contraceptive use on innate immune activation among women with IBS requires further research.

Keywords

irritable bowel syndrome cytokines contraception hormonal contraception symptoms

Get full access to this article

View all access options for this article.

References

Bashashati

Moradi

Sarosiek

(2017). Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine, 99, 132–138. https://doi.org/10.1016/j.cyto.2017.08.017

Bashashati

Rezaei

Andrews

C. N.

Chen

C. Q.

Daryani

N. E.

Sharkey

K. A.

Storr

M. A.

(2012). Cytokines and irritable bowel syndrome: Where do we stand? Cytokine, 57(2), 201–209. https://doi.org/10.1016/j.cyto.2011.11.019

Bashashati

Rezaei

Shafieyoun

McKernan

D. P.

Chang

Ohman

Quigley

E. M.

Schmulson

Sharkey

K. A.

Simren

(2014). Cytokine imbalance in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterology & Motility, 26(7), 1036–1048. https://doi.org/10.1111/nmo.12358

Bennet

S. M.

Polster

Törnblom

Isaksson

Capronnier

Tessier

Le Nevé

Simrén

Öhman

(2016). Global cytokine profiles and association with clinical characteristics in patients with Irritable Bowel Syndrome. The American Journal of Gastroenterology, 111(8), 1165–1176. https://doi.org/10.1038/ajg.2016.223

Bennet

Palsson

Whitehead

W. E.

Barrow

D. A.

Törnblom

Öhman

Simrén

van Tilburg

(2018). Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. Neurogastroenterology and Motility, 30(10), e13378. https://doi.org/10.1111/nmo.13378

Bharadwaj

Barber

M. D.

Graff

L. A.

Shen

(2015). Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle. Gastroenterology Report, 3(3), 185–193. https://doi.org/10.1093/gastro/gov010

Bjelland

Dahl

A. A.

Haug

T. T.

Neckelmann

. (2002). The validity of the Hospital anxiety and depression scale. An updated literature review. Journal of Psychosomatic Research, 52(2), 69–77. https://doi.org/10.1016/s0022-3999(01)00296-3

Camilleri

(2020). Sex as a biological variable in irritable bowel syndrome. Neurogastroenterology & Motility, e13802. https://doi.org/10.1111/nmo.13802

Chang

Adeyemo

Karagiannides

Videlock

E. J.

Bowe

Shih

Presson

A. P.

Yuan

P. Q.

Cortina

Gong

Singh

Licudine

Mayer

Tache

Pothoulakis

Mayer

E. A.

(2012). Serum and colonic mucosal immune markers in irritable bowel syndrome. American Journal of Gastroenterology, 107(2), 262–272. https://doi.org/10.1038/ajg.2011.423

10.

Choghakhori

Abbasnezhad

Hasanvand

Amani

(2017). Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life. Cytokine, 93, 34–43. https://doi.org/10.1016/j.cyto.2017.05.005

11.

Clarke

O’Mahony

S. M.

Hennessy

A. A.

Ross

Stanton

Cryan

J. F.

Dinan

T. G.

(2009). Chain reactions: Early-life stress alters the metabolic profile of plasma polyunsaturated fatty acids in adulthood. Behavioural Brain Research, 205(1), 319–321. https://doi.org/10.1016/j.bbr.2009.07.008

12.

Collins

S. M.

Piche

Rampal

(2001). The putative role of inflammation in the irritable bowel syndrome. Gut, 49(6), 743–745. https://doi.org/10.1136/gut.49.6.743

13.

Cooper

D. B.

Mahdy

. (2020). Oral contraceptive pills. StatPearls Publishing.

14.

Cowie

A. M.

Dittel

B. N.

Stucky

C. L.

(2019). A novel sex-dependent target for the treatment of postoperative pain: The NLRP3 inflammasome. Frontiers in Neurology, 10, 622.

15.

Cremon

Gargano

Morselli-Labate

A. M.

Santini

Cogliandro

R. F.

De Giorgio

Barbara

. (2009). Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. American Journal of Gastroenterology, 104(2), 392–400. https://doi.org/10.1038/ajg.2008.94

16.

Daniels

Abma

J. C.

(2018). Current contraceptive status among women aged 15–49: United States, 2015–2017. https://www.cdc.gov/nchs/products/databriefs/db327.htm

17.

Decker

Gotta

Wellmann

Ritz

(2017). Cytokine profiling in healthy children shows association of age with cytokine concentrations. Scientific Reports, 7, 17842. https://doi.org/10.1038/s41598-017-17865-2

18.

Dinan

T. G.

Clarke

Quigley

E. M.

Scott

L. V.

Shanahan

Cryan

Cooney

Keeling

P. W.

(2008). Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. The American Journal of Gastroenterology, 103(10), 2570–2576. https://doi.org/10.1111/j.1572-0241.2008.01871.x

19.

Drossman

D. A

. (2016). Functional gastrointestinal disorders: history, pathophysiology, clinical features and rome IV. Gastroenterology. https://doi.org/10.1053/j.gastro.2016.02.032

20.

Han

C. J.

Jarrett

M. E.

Cain

K. C.

Jun

Heitkemper

M. M.

(2018). Association of fatigue with TPH2 genetic polymorphisms in women with irritable bowel syndrome. Biological Research for Nursing. https://doi.org/10.1177/1099800418806055

21.

Han

C. J.

Jarrett

M. E.

Heitkemper

M. M.

(2020). Relationships between abdominal pain and fatigue with psychological distress as a mediator in women with Irritable Bowel Syndrome. Gastroenterology Nursing, 43(1), 28–39. https://doi.org/10.1097/SGA.0000000000000383

22.

Han

C. J.

Pike

Jarrett

M. E.

Heitkemper

M. M.

(2019). Symptom-based latent classes of persons with irritable bowel syndrome. Research in Nursing and Health, 42(5), 382–391. https://doi.org/10.1002/nur.21974

23.

Heitkemper

M. M.

Cain

K. C.

Jarrett

M. E.

Burr

R. L.

Hertig

Bond

E. F.

(2003). Symptoms across the menstrual cycle in women with irritable bowel syndrome. The American Journal of Gastroenterology, 98(2), 420–430. https://doi.org/10.1111/j.1572-0241.2003.07233.x

24.

Himmerich

Patsalos

Lichtblau

Ibrahim

Dalton

(2019). Cytokine research in depression: Principles, challenges, and open questions. Frontiers in Psychiatry, 10, 30. https://doi.org/10.3389/fpsyt.2019.00030

25.

Hua

M. C.

Lai

M. W.

Kuo

M. L.

Yao

T. C.

Huang

J. L.

Chen

S. M.

(2011). Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. Journal of Pediatric Gastroenterology and Nutrition, 52(4), 376–381. https://doi.org/10.1097/MPG.0b013e3181fd9816

26.

Irwin

M. R.

(2011). Inflammation at the intersection of behavior and somatic symptoms. Psychiatric Clinics of North America, 34(3), 605–620. https://doi.org/10.1016/j.psc.2011.05.005

27.

Jansky

Reymanova

Kopecky

(2003). Dynamics of cytokine production in human peripheral blood mononuclear cells stimulated by LPS or infected by Borrelia. Physiological Research, 52(6), 593–598.

28.

Jarrett

M. E.

Cain

K. C.

Barney

P. G.

Burr

R. L.

Naliboff

B. D.

Shulman

Zia

Heitkemper

M. M.

(2016). Balance of autonomic nervous system predicts who benefits from a self-management intervention program for irritable bowel syndrome. Journal of Neurogastroenterology and Motility, 22(1), 102–111. https://doi.org/10.5056/jnm15067

29.

Jarrett

M. E.

Cain

K. C.

Burr

R. L.

Hertig

V. L.

Rosen

S. N.

Heitkemper

M. M.

(2009). Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. The American journal of gastroenterology, 104(12), 3004–3014. https://doi.org/10.1038/ajg.2009.479

30.

Jiang

Greenwood-Van Meerveld

Johnson

A. C.

Travagli

R. A.

(2019). Role of estrogen and stress on the brain-gut axis. American Journal of Physiology: Gastrointestinal and Liver Physiology, 317(2), G203–g209. https://doi.org/10.1152/ajpgi.00144.2019

31.

Kim

Y. S.

Kim

(2018). Sex-gender differences in irritable bowel syndrome. Journal of Neurogastroenterology and Motility, 24(4), 544–558. https://doi.org/10.5056/jnm18082

32.

Kovats

(2015). Estrogen receptors regulate innate immune cells and signaling pathways. Cellular Immunology, 294(2), 63–69. https://doi.org/10.1016/j.cellimm.2015.01.018

33.

Kroenke

Spitzer

R. L.

Williams

J. B.

(2002). The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine, 64(2), 258–266.

34.

Lazaridis

Germanidis

(2018). Current insights into the innate immune system dysfunction in irritable bowel syndrome. Annals of Gastroenterology, 31(2), 171–187. https://doi.org/10.20524/aog.2018.0229

35.

Lee

J. Y.

Kim

Park

J. H.

Nam

R. H.

Lee

S. M.

Song

C.-H.

Kim

H. Y.

Choi

Y. J .

Kim

J. J.

Lee

D. H.

(2020). Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex. Journal of Neurogastroenterology and Motility, 26(1), 106–116. https://doi.org/10.5056/jnm19099

36.

Liebregts

Adam

Bredack

Roth

Heinzel

Lester

Downie-Doyle

Smith

Drew

Talley

N. J.

Holtmann

. (2007). Immune activation in patients with irritable bowel syndrome. Gastroenterology, 132(3), 913–920. https://doi.org/10.1053/j.gastro.2007.01.046

37.

Longstreth

G. F.

Thompson

W. G.

Chey

W. D.

Houghton

L. A.

Mearin

Spiller

R. C.

(2006). Functional bowel disorders. Gastroenterology, 130(5), 1480–1491.

38.

Lovell

R. M.

Ford

A. C.

(2012). Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical Gastroenterology and Hepatology, 10(7), 712–721.e714. https://doi.org/10.1016/j.cgh.2012.02.029

39.

Martin-Vinas

J. J.

Quigley

E. M.

(2016). Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators. Journal of Digestive Diseases, 17(9), 572–581. https://doi.org/10.1111/1751-2980.12379

40.

Mulak

Tache

Larauche

(2014). Sex hormones in the modulation of irritable bowel syndrome. World Journal of Gastroenterology, 20(10), 2433–2448. https://doi.org/10.3748/wjg.v20.i10.2433

41.

Nasser

Petes

Simmers

Basso

Altier

Gee

Vanner

S. J.

(2019). Activation of peripheral blood CD4+ T-Cells in IBS is not associated with gastrointestinal or psychological symptoms. Scientific Reports, 9(1), 3710. https://doi.org/10.1038/s41598-019-40124-5

42.

Poulsen

C. H.

Eplov

L. F.

Hjorthøj

Hastrup

L. H.

Eliasen

Dantoft

T. M.

Schröder

Jørgensen

(2019). Irritable bowel symptoms, use of healthcare, costs, sickness and disability pension benefits: A long-term population-based study. Scandinavian Journal of Public Health, 47(8), 867–875. https://doi.org/10.1177/1403494818776168

43.

Rana

S. V.

Sharma

Sinha

S. K.

Parsad

K. K.

Malik

Singh

. (2012). Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Tropical Gastroenterology, 33(4), 251–256. https://doi.org/10.7869/tg.2012.66

44.

Ribeiro-Dasilva

M. C.

Fillingim

R. B.

Wallet

S. M.

(2017). Estrogen-induced monocytic response correlates with TMD pain: a case control study. Journal of Dental Research, 96(3), 285–291. https://doi.org/10.1177/0022034516678599

45.

Schmulson

Pulido-London

Rodriguez

Morales-Rochlin

Martinez-Garcia

Gutierrez-Ruiz

M. C.

López-Alvarenga

J. S.

Gutierrez-Reyes

(2012). Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. American Journal of Gastroenterology, 107(5), 747–753. https://doi.org/10.1038/ajg.2011.484

46.

Seyedmirzaee

Hayatbakhsh

M. M.

Ahmadi

Baniasadi

Bagheri Rafsanjani

A. M.

Nikpoor

A. R.

Mohammadi

(2016). Serum immune biomarkers in irritable bowel syndrome. Clinics and Research in Hepatology and Gastroenterology, 40(5), 631–637. https://doi.org/10.1016/j.clinre.2015.12.013

47.

Shulman

R. J.

Eakin

M. N.

Czyzewski

D. I.

Jarrett

C. N.

(2008). Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. Journal of Pediatrics, 153(5), 646–650. https://doi.org/10.1016/j.jpeds.2008.04.062

48.

Shulman

R. J.

Jarrett

M. E.

Cain

K. C.

Broussard

E. K.

Heitkemper

M. M.

(2014). Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. Journal of Gastroenterology, 49(11), 1467–1476. https://doi.org/10.1007/s00535-013-0919-6

49.

Straub

R. H.

(2007). The complex role of estrogens in inflammation. Endocrine Reviews, 28(5), 521–574. https://doi.org/10.1210/er.2007-0001

50.

Zhang

Zein

(2019). Novel insights on sex-related differences in asthma. Current Allergy and Asthma Reports, 19(10), 44. https://doi.org/10.1007/s11882-019-0878-y

51.

Zigmond

A. S.

Snaith

R. P.

(1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.